At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
10ppm Oral Silver Particle +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In Vivo Assessment of Silver Biomaterial Nano-Toxicity
In Brief
A Phase 2 clinical trial evaluating 10ppm Oral Silver Particle and 32ppm Oral Silver Particle for Healthy. Completed, enrolled 36 participants across 1 site.
Detailed Summary
Nanotechnology is the controlled generation and manipulation of matter in dimensions less than 100 nm. Silver has been used for its bactericidal properties. The investigators propose to study the American Biotech Laboratory 32 ppm silver solution over a 14-day period in human volunteers to determine the toxicity and to quantify cytochrome P450 enzyme effects of this solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartDec 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedNov 18, 2010
Enrollment StartDec 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.6 years ago
Interventions
10ppm Oral Silver Particledrug
Silver nanoparticles at 10ppm
32ppm Oral Silver Particledrug
Silver nanoparticles at 32ppm